Drug Approval | December 27, 2021
Covaxin receives approval for Emergency Use in Children 12-18 years
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Covaxin is formulated uniquely such that the same dosage can be administered to adults and children
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
The Drug Controller General of India (DCGI), is reviewing clinical data of molnupiravir for the treatment of Covid-19 in adults in India
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
Subscribe To Our Newsletter & Stay Updated
